LETTER TO THE EDITOR

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder

Huijun Huang†, Wenjun Zhang†, Wenyu Cai2, Jinqin Liu1, Huijun Wang2, Tiejun Qin3, Zefeng Xu1,3,4, Bing Li1,3,4, Shiqiang Qu1,3,4, Lijuan Pan3,4, Gang Huang5, Robert Peter Gale6 and Zhijian Xiao1,3,4*

Abstract

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly-described adult-onset inflammatory syndrome characterized by vacuoles in myeloid and erythroid precursor cells and somatic mutations affecting methionine-41 (p.Met41) in UBA1. The VEXAS syndrome often overlaps with myelodysplastic syndromes (MDS) with autoimmune disorders (AD). By screening the UBA1 gene sequences derived from MDS patients with AD from our center, we identified one patient with a p.Met41Leu missense mutation in UBA1, who should have been diagnosed as MDS comorbid with VEXAS syndrome. This patient respond poorly to immune suppressive drugs. Patients with MDS and AD who have characteristic vacuoles in myeloid and erythroid precursor cells should be screened for UBA1 mutation, these patients are likely to have VEXAS syndrome and unlikely to improve with immunosuppressive drugs and should be considered for other alternative therapies.

Keywords: Myelodysplastic syndromes, Autoimmune disorders, VEXAS syndrome, UBA1 mutation, Cytoplasmic vacuolation

To the Editor,

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly-described adult-onset inflammatory syndrome characterized by fevers, cytopenias, vacuoles in myeloid and erythroid precursor cells, dysplastic bone marrow, neutrophilic cutaneous and pulmonary infiltrates, nose and ear chondritis and vasculitis. The syndrome is associated with somatic mutations affecting methionine-41 (p.Met41) in UBA1, an X-chromosome gene encoding ubiquitin-like modififier-activating enzyme 1 [1]. Among the initial 25 patients reported with VEXAS syndrome, 6 met the World Health Organization (WHO) diagnostic criteria for myelodysplastic syndromes (MDS). In another study of 15 patients with VEXAS syndrome 5 had MDS [2]. These data indicate substantial overlap between VEXAS syndrome and MDS. Other data indicate an increased incidence of other autoimmune disorders (AD) in patients with hematological malignancies [3, 4], especially MDS [5–7]. In this study, we screened the UBA1 gene sequences derived from MDS patients with confirmed AD from our center and identified one patient with a p.Met41Leu missense mutation in UBA1, who should have been diagnosed as MDS comorbid with VEXAS syndrome.

Five hundred and fourteen consecutive subjects with MDS from January 2013 to December 2019 were included in this study. Medical records were reviewed for evidence of an autoimmune disorder. Diagnosis of MDS was made according to 2016 revised WHO criteria [8]. Wright-Giemsa-stained blood and bone marrow slides were evaluated by two expert pathologists. Serum samples from 248 subjects (48%) were tested for cytokine levels. Blood samples from 216 (42%) subjects
were assayed for lymphocyte sub-populations by multi-parameter flow cytometry (MPFC). Four hundred thirty-nine subjects (85%) with cytogenetics data were evaluated using the Revised International Prognostic Scoring System (IPSS-R) [9]. DNA from bone marrow mononuclear cells from 275 subjects (54%) underwent targeted 112-gene next generation sequencing (NGS) at diagnosis (Additional file 1: Table S1). All subjects provided informed consent in compliance with the Declaration of Helsinki.

Eighty-five subjects (16.5%) had an autoimmune disorder before their MDS diagnosis. The most common AD in MDS was rheumatoid arthritis (16, 18.8%), followed by psoriasis (14, 16.5%), hypothyroidism (10, 11.8%) and Behcet syndrome (9, 10.6%) (Additional file 1: Table S2). Co-variates of all subjects are displayed in Table 1. Having an autoimmune disorder was associated with female gender ($p=0.024$), higher frequency of trisomy 8 ($p=0.001$) and a lower ratio of helper to suppressor T-cells (CD4/CD8 ratio; $p=0.032$). Other co-variates

| Table 1 | Clinical and laboratory characteristics of MDS patients with and without autoimmune disorders (AD) |
|----------|---------------------------------------------------------------------------------|
| Characteristics | MDS with AD ($n=85$) | MDS without AD ($n=429$) | Total ($n=514$) | $P$ value |
| Sex(%) | | | | 0.024 |
| Male | 37(43.5) | 245(57.1) | 282(54.9) | |
| Female | 48(56.5) | 184(42.9) | 232(45.1) | |
| Age, median (range), y | 55(22–78) | 57(7–84) | 56(7–84) | 0.538 |
| WHO classification 2016(%) | | | | 0.719 |
| MDS-SLD | 3(3.5) | 19(4.4) | 22(4.3) | |
| MDS-SLD-RS | 2(2.4) | 16(3.7) | 18(3.5) | |
| MDS-MLD | 46(54.1) | 224(52.2) | 270(52.5) | |
| MDS-MLD-RS | 4(4.7) | 11(2.6) | 15(2.9) | |
| MDS-EB1 | 17(20.0) | 79(18.4) | 96(18.7) | |
| MDS-EB2 | 9(10.6) | 63(14.7) | 72(14.0) | |
| MDS with isolated del(5q) | 0 | 6(1.4) | 6(1.2) | |
| MDS-U | 4(4.7) | 11(2.6) | 15(2.9) | |
| Hb, median (range), g/L | 79(41–155) | 80(26–165) | 80(26–165) | 0.535 |
| WBC, median (range), $\times 10^9$/L | 2.8(0.32–27.95) | 2.78(0.41–25.45) | 2.79(0.32–27.95) | 0.786 |
| ANC, median (range), $\times 10^9$/L | 1.14(0–6.52) | 1.16(0–20.53) | 1.16(0–20.53) | 0.658 |
| PLT, median (range), $\times 10^9$/L | 60(6–487) | 62(2–603) | 61(2–603) | 0.912 |
| BM blast, median (range), % | 2.25(0–18) | 2.50(0–19.5) | 2.50(0–19.5) | 0.618 |
| CD4/CD8 T cell ratio | 1.35(0.42–5.91) | 1.67(0.37–8.42) | 1.59(0.37–8.42) | 0.032 |
| Serum IL-6, pg/ml | 6.22(2–31.5) | 5.19(2–188) | 5.28(2–188) | 0.904 |
| Serum TNF-α, pg/ml | 21.6(4–1000) | 14.9(4–478) | 16.3(4–1000) | 0.04 |
| IPSS-R karyotype types ($n=439$) | | | | 0.341 |
| Very good | 0 | 3(0.8) | 3(0.7) | |
| Good | 36(50) | 216(58.9) | 252(57.4) | |
| Intermediate | 25(34.7) | 86(23.4) | 111(25.3) | |
| Poor | 4(6.3) | 19(5.2) | 23(5.2) | |
| Very poor | 7(9.7) | 43(11.7) | 50(11.4) | |
| Trisomy 8 positive(%) | 22(30.6) | 45(12.3) | 67(15.3) | 0.001 |
| IPSS-R risk group types ($n=439$) | | | | 0.558 |
| Very low | 0 | 12(3.3) | 12(2.7) | |
| Low | 21(29.2) | 109(29.7) | 130(29.6) | |
| Intermediate | 27(37.5) | 114(31.1) | 141(32.1) | |
| High | 15(20.8) | 77(21.0) | 92(21.0) | |
| Very high | 9(12.5) | 55(15.0) | 64(14.6) | |

MDS-SLD, MDS with single lineage dysplasia; MDS-RS, MDS with ring sideroblasts with single lineage dysplasia; MDS-MLD, MDS with multilineage dysplasia; MDS-RS-MLD, MDS with ring sideroblasts with multilineage dysplasia; MDS-EB1, MDS with excess blasts-1; MDS-EB2, MDS with excess blasts-2; MDS-U, MDS unclassifiable; Hb, haemoglobin; WBC, white blood count; ANC, absolute neutrophil count; PLT, platelet count; BM, bone marrow; IL-6, interleukin-6; TNF-α, α-tumor necrosis factor; IPSS-R, Revised International Prognostic Scoring System
were similar. Data from NGS showed no difference in mutation topography (Fig. 1a, b).

Sanger sequencing for variants of interest in UBA1 were performed in 47 patients who were diagnosed with AD and had available bone marrow DNA samples. Genomic DNA were extracted using TIANamp Genomic DNA Kit (TIANGEN DP304) according to the manufacturer’s instruction. PCR and Sequencing primers (For 5'-TCACCTCTGACCTTTTTTTC-3', Rev 5'-ATGTTCTTAGCGATCTCCAC-3') were designed using Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, CA, USA). UBA1 p.Met41 somatic mutations were detected by PCR performed with 2 × Hieff Robust PCR Master Mix (YEASEN 10106ES03). The PCR amplicons were then purified and Sanger sequenced using the ABI 3730XL (Applied Biosystems). Sequencing data were analyzed using Chromas (version 2.6.5, Technelysium Pty Ltd, USA) and all chromatograms shown are derived from Chromas.

A somatic variant in UBA1 codon 41 (p.Met41Leu [NM_003334.3:c.121A→C]) (Fig. 1c) was detected in a 61-year-old male with rheumatoid arthritis diagnosed in local hospital 6 years ago and was seen by us because of cytopenias and macrocytic anaemia. The full blood count showed a hemoglobin of 67 g/L, MCV of 127.4 fl, WBC of 4.21 × 10⁹/L and platelet of 77 × 10⁹/L. A bone marrow aspirate showed hyper-cellularity with increases in all lineages without excess blasts with prominent dysplasia including pseudo-Pelger–Huët anomaly in neutrophils, megaloblastoid change and nuclear abnormalities in erythroid precursor cells and micro-megakaryocytes (Fig. 1d). There were no ringed sideroblasts. Typical cytoplasmic vacuolation of VEXAS syndrome were seen in myeloid and erythroid precursor cells (Fig. 1d). The karyotype was 46, XY[20]. No other somatic mutation was detected in NGS. He had an increased blood concentration of interleukin-6 (IL-6; 14.5 pg/mL) and α-tumor necrosis factor (TNF-α; 9.56 pg/ml).

The subject was diagnosed with MDS with multi-lineage dysplasia (MDS-MLD) with low risk group in IPSS-R. He received cyclosporine, danazol, thalidomide, low-dose prednisolone (below 10 mg/day) and RBC-transfusions. There was no haematologic improvement at 1 year and he remained RBC-transfusion-dependent at last follow-up on February 5, 2021.

Cytoplasmic vacuolation in hematopoietic cells is a non-specific abnormality seen in several diseases including MDS, sideroblastic anaemia, copper deficiency, zinc excess and acute alcohol exposure [10–13]. Different mechanisms of formation result in vacuoles with diverse histological features and distributions. One study reported vacuoles in patients with MDS are often of irregular shape with indistinct outlines and a tendency.
Mutations affecting p.Met41 result in loss of the canonical cytoplasmic isoform of \textit{UBA1} leading to decreased ubiquitylation, activated innate immune pathways and systemic inflammation. In one series no subject with VEXAS syndrome responded to disease-modifying anti-inflammatory drugs, while all were high-dose glucocorticoids-dependent [1]. In this series 10 of 25 subjects died from disease-related causes such as progressive anemia or therapy-related complications. In another study subjects with MDS and systemic inflammatory and autoimmune disorders were often steroid dependent [7]. Our patient concomitant with VEXAS syndrome also had poor hematologic response to immunosuppressive drugs and low-dose prednisolone.

In conclusion, patients with pan autoimmune disorders, especially those with typical VEXAS-related cytoplasmic vacuoles, should be tested for \textit{UBA1} mutation. MDS patients with \textit{UBA1} p.Met41 mutation probably have a poor prognosis regardless of a low IPSS-R score, and are unlikely to improve with immunosuppressive or hypo-methylating drugs and should be considered for alternative therapies including participation in clinical trials.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40164-021-00217-2.

Additional file 1: Table S1. Gene list of the 112-gene panel. Table S2. Frequency of autoimmune disorders identified in patients with MDS.

Acknowledgements
This study is supported in part by National Natural Science Funds (No. 81870104), Tianjin Natural Science Funds (18JCZDJC34000,16JCQNJC11400, 19JQNCJC09400), CAMS Initiative Fund for Medical Sciences (No.2020-I2M-C&T-A-020).

Authors’ contributions
ZJX designed the research, was the principal investigator, and took primary responsibility for the paper; ZJX, HJH, WJZ, WYC and HJW acquired the data, analysed and interpreted the data, performed statistical analysis and drafted the article; ZJX, TJQ, ZFX, BL, LJP and SQQ recruited the patients; ZJX, GH and RPG prepared the manuscript. All authors read and approved the final manuscript.

Availability of data and materials
The single institute data from this study is available from the corresponding author upon reasonable request.

Declarations
Ethics declarations
his study was approved by Ethical Committee on Medical Research at Institute of Hematology and blood disease hospital.

Competing interest
The authors declare no competing financial interests.

Author details
1 State Key Laboratory of Experimental Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. 2 Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. 3 MDS and MPN Centre, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, 288 Nanjing Road, Tianjin 300020, China. 4 National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. 5 Divisions of Experimental Haematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. 6 Division of Experimental Medicine, Department of Medicine, Haematology Section, Imperial College London, London, UK.

Received: 17 February 2021 Accepted: 12 March 2021
Published online: 19 March 2021

References:
1. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med. 2020;383(27):2628–38.
2. Obiorah IE, Beck DB, Wang W, Ombrello A, Ferrada MA, Wu Z, et al. Myelodysplasia and Bone Marrow Manifestations of Somatic UBA1 Mutated Autoinflammatory Disease. Blood. 2020;136(Suppl 1):20–1.
3. Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K. Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. J Hematol Oncol. 2012;5:39.
4. Brito-Zerón P, Kostov B, Fraile G, Caravia-Durán D, Maure B, Rascón FJ, et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol. 2017;10(1):90.
5. Montoro J, Gallur L, Merchán B, Molero A, Roldán E, Martínez-Valle F, et al. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Ann Hematol. 2018;97(S):1349–56.
6. Boddu PC, Zeidan AM. Myeloid disorders after autoimmune disease[J]. Best Pract Res Clin Haematol. 2019;32(1):74–88.
7. Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Cootedoat-Chaumeau N, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study[J]. Rheumatology (Oxford). 2016;55(2):291–300.
8. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.
9. Greenberg PL, Tuechler H, Scharf J, Sanz G, Garcia-Manero G, Sfeir F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.
10. Goasguen JE, Bennett JM, Bain BJ, Brunner R, Vallespi MT, Tomonaga M, et al. Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas. Br J Haematol. 2018;182(4):526–33.
11. Gregg XT, Reddy V, Prchal JT. Copper deficiency masquerading as myelodysplastic syndrome. Blood. 2002;100(4):1493–5.

12. Broun ER, Greist A, Tricot G, Hoffman R. Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. JAMA. 1990;264(11):1441–1443.

13. Yeung KY, Klug PP, Lessin LS. Alcohol-induced vacuolization in bone marrow cells: ultrastructure and mechanism of formation. Blood Cells. 1988;13(3):487–502.

14. Fan BE, Cao L, Gallardo CA, Lee S, Koh LW, Goh LL, et al. Myeloid and Lymphoid Vacuolation in VEXAS syndrome. Am J Hematol. 2021. https://doi.org/10.1002/ajh.26098.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.